imatinib
Ligand Summary
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
UNII: BKJ8M8G5HI
PubChem: 5291
Guide to Pharmacology: 5687
ChEMBL: CHEMBL941
DrugCentral: 1423
LyCHI: VLU17BQBSGWU
Target Activities
86 Activities
Items per page:
10
1 – 10 of 86
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
Ki | ||||||
Ki | ||||||
Ki | ||||||
IC50 | ||||||
Kd | ||||||
Kd | ||||||
Kd | ||||||